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Abstract
Background. Since the regenerative medicine sector entered the second phase of its development (RegenMed 2.0) more
than a decade ago, there is increasing recognition that current technology innovation trajectories will drive the next trans-
lational phase toward the production of disruptive, high-value curative cell and gene-based regenerative medicines. Aim. To
identify the manufacturing science problems that must be addressed to permit translation of these next generation therapeutics.
Method. In this short report, a long lens look within the pluripotent stem cell therapeutic space, both embryonic and induced,
is used to gain early insights on where critical technology and manufacturing challenges may emerge. Conclusion. This report
offers a future perspective on the development and innovation that will be needed within manufacturing science to add
value in the production and commercialization of the next generation of advanced cell therapies and precision medicines.
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Introduction
Since the regenerative medicine sector entered the
second phase of its development (RegenMed 2.0),
which marked a step change in translation more than
a decade ago [1], there is increasing recognition that
current technology innovation trajectories will drive
the next phase of the industry toward the produc-
tion of disruptive cell and gene-based therapies that
shift the therapeutic paradigm from symptomatic or
disease-modifying treatments to high-value, reimburs-
able curative medicines [2,3]. In an industrial context,
while this transition offers business growth paths with
more certainty of high rewards, it may require an equiv-
alent step change in translational capability if the
industry is to be ready for the next wave of manu-
facturing and supply chain challenges that this new
generation of regenerative medicines will bring. In this
short report a long lens look within the pluripotent
stem cell (PSC) therapeutic space is used to gain early
strategic insights on where these manufacturing chal-
lenges are likely to emerge and to draw future
perspectives on the need for reformulated or new
manufacturing science.
In the last ten years, significant technological pro-
gress has been made in the PSC therapeutic space
[4,5], with human induced pluripotent stem cell (iPSC)
technology as a new source of patient-specific ther-
apeutic cells, potentially free from the ethical concerns,
legislative issues and immune rejection barriers of
human embryonic stem cells (hESCs) and their
somatic cell nuclear transfer hESC counterparts, be-
ginning to dominate the field [6].This has been driven
by limitations in the availability of most specialist
somatic cells and current restrictions in the expan-
sion of adult stem cells together with their associated
heterogeneity arising from sources such as bone
marrow [7–9].
Advances in iPSC technology, coupled with recent
breakthroughs in gene editing and ability to provide
highly engineered, developmentally inspired cellular
microenvironments (niches) through advances in tissue
engineering, by bringing regenerative medicine and
gene therapy closer, are expected to substantially
broaden the clinical scope of the field over the next
decade [3,5,10]. This envisions a natural innovation
trajectory toward the development of more precise,
highly engineered PSC-derived combination products
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and targeted combinatorial therapeutic strategies that
have the potential to deliver enhanced safety and ef-
ficacy attributes (i.e., by combining cells with other
integral or synergistically delivered components that
may contribute to the mode of action and the intend-
ed therapeutic effect).
Convergent with rapid innovation in pharma-
cogenomics and molecular diagnostics (‘-omics’)
screening technologies and the impressive momen-
tum in other technology innovation trajectories (e.g.
adoptive cancer immunotherapies), this evolution pro-
vides general pointers to the core manufacturing and
operational innovations that may be needed to un-
derpin the production of the next generation of cell
and gene-based regenerative and precision medicines.
By considering approaches to how the conver-
gence of multiple underlying enabling technology
options may be brought together for the generation
and configuration of the next generation of iPSC-
derived cell and gene-based product technology
concepts, we summarized the new and emerging manu-
facturing science challenges that need to be addressed
to accelerate their transition from research and de-
velopment (R&D) to clinical stage bioprocessing.We
examined the main scientific/technical challenges
related to the intrinsic engineered cellular features of
the underlying product technologies and the corre-
sponding risks to manufacturability and producibility.
Special attention was given to a broad systems engi-
neering perspective on the maturity of the capability
and readiness of the individual underlying product tech-
nologies (Technology Readiness Level [TRL]) to
deliver their function and the readiness of the corre-
sponding manufacturing systems and/or processes for
production (Manufacturing Readiness Level [MRL]).
The assignment of TRLs and MRLs is not absolute
and is intended to provide a broad indicator of rela-
tive maturity to assist a comparison of the challenges
associated with technology-manufacturing transi-
tions across multiple product candidates, based on
current scientific knowledge, clinical experience and
industry practice.
The challenges to advancing product
technology maturity within the PSC
therapeutic space
The future landscape for candidate iPSC-derived cell
and gene-based therapeutic products
The convergence of multiple enabling technology
options is providing scope for the development and
production of a range of different iPSC-derived cell
product technology concepts, applicable to therapeu-
tic modalities ranging from simply transplanting
terminally differentiated engineered cells to reseeding
decellularized organs or reconstructing 2-dimensional
(2D) or 3-dimensional (3D) functional living tissues/
organs.Approaches to the generation and configuration
of candidate iPSC-derived therapeutic product con-
cepts are shown in Figure 1.This illustrates how the
integral functional component parts and their under-
lying enabling technologies may be brought together
and integrated.
Focussed on the derivation of terminally differ-
entiated PSC-derived cells for 2D and 3D cell
therapeutic applications rather than on the direct use
of undifferentiated PSCs or their cell- free deriva-
tives (e.g., exosomes), this logic imagines five major
PSC-derived product technology candidate concept
areas: iPSC-derived cell-based technology, gene-
modified iPSC-derived cell-based technology, iPSC-
derived organoid-based technology, gene-modified
iPSC-derived organoid technology and iPSC-derived
3D tissue–engineered technology.These concepts are
founded on the manufacture of different cell-based
functional elements that comprise [1] the derivation
of primed and naïve-state iPSCs from reprogrammed
human somatic cells [2], the expansion and terminal
differentiation of iPSCs into cell types of interest [3],
the genetic engineering or gene editing of iPSCs [4],
the encapsulation of iPSC-derived therapeutic cells in
fabricated 3D scaffolds for engraftment or cell deliv-
ery and [5] the generation of tissue-specific 3D
organoids from iPSCs.
Challenges to transitioning product technology maturity
Many of the configurations in Figure 1 are clearly rel-
evant to an array of applications in healthcare, with
experimental proof-of-concept having already been
achieved pre-clinically for many of the different func-
tional elements. Primed state iPSCs, for example, have
been generated from a variety of different human
somatic cell types, such as blood cells, fibroblasts and
keratinocytes, to derive a range of PSC-derived
terminally differentiated cell types, including
cardiomyocytes, motor neurons and insulin-producing
pancreatic cells.Their therapeutic potential has been
evaluated in several pre-clinical animal studies and
human disease models [4,5].Ex vivo gene-editing tech-
nologies and clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) technology, in particular, have been
widely used in iPSCs and PSC-derived organoid cul-
tures, with a growing list of proof-of-concept and pre-
clinical studies demonstrating therapeutic potential for
single-gene hereditary diseases, such as cystic fibro-
sis or β-thalassemia [11–15].
However, with little clinical experience using iPSC-
derived cells compared with hESCs, significant quality
and safety risks related to the asymmetric maturity of
the underlying technologies remain [4,5]. An
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understanding of these technology-related risks brings
into view the technical and scientific challenges that
need to be addressed to transition these relatively im-
mature product technologies (TRL 1 toTRL 3) to a
level of readiness sufficient for incorporation into a
product development program and entry to phase 1
clinical trials in humans (TRL 5). To assist a strate-
gic perspective, the snapshot in Figure 2 provides a
high-level view of the level of technology maturity
across five major PSC-derived product technology
concept areas, based on the intrinsic capability fea-
tures of the underlying technologies to deliver their
function [16]. A consideration of the main quality and
safety risks associated with the ex vivo manipulation
of the cellular component and its niche allows the fol-
lowing future perspectives for transitioning product
technology maturity within the PSC therapeutic space
to be drawn.
Persistent risks associated with the unpredictable
potential for tumourigenicity and immunogenicity con-
tinue to raise challenges for the current generation of
cell plasticity (iPSC reprogramming, expansion, ter-
minal differentiation) and gene-editing technologies.
The potential for tumourigenicity primarily arises
from random insertion of integrating reprogram-
ming vectors, off-target mutagenesis from gene editing
and risk of teratomas arising from transfer of residual
undifferentiated or defective iPSCs. The develop-
ment of second-generation, non-integrating iPSC
reprogramming methods has reduced the risk of
tumourigenicity arising from the random insertional
mutagenesis associated with their integrating
Figure 1. Schematic of approaches to generate candidate iPSC–derived cell and gene-based therapeutic products. Somatic cells isolated
from tissue acquired from a patient within a stratified disease subgroup (predictive biomarker(s) identified via a companion diagnostic
[CDx]) or from an eligible normal healthy donor are reprogrammed into iPSCs and/or converted to naïve state (n-iPSC). Genetic defects
in iPSCs or n-iPSCs can be corrected or the cells can be enriched using gene-editing technology (e-iPSC). Subsequently, iPSCs with or
without edited modifications are differentiated into multiple target tissue-specific 3D organoids (inducted with exogenous self-
organization signalling cues) or 2D cell lines before being transferred back to the patient as functional organ-like units or as a cell suspension,
respectively. An alternative is to seed biomaterials or acellular pre-formed scaffolds (fabricated from synthetic or naturally derived) with
terminally differentiated 3D organoids or 2D cells to form general-form biomimetic structures or customized 3D tissue–engineered con-
structs for implantation. These constructs can be combined with other integral or synergistically delivered active components or medical
device technologies to further refine their development and functionality before, during or after transplantation into the patient.
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virus-based predecessors [17,18]. Nevertheless, further
technology advances are required to overcome current
limitations associated with incomplete reprogram-
ming, as well as low reprogramming and differentiation
efficiencies that result in heterogeneous populations
and low yields of reprogrammed cells.
Continued improvement in the understanding of
the molecular mechanisms underlying reprogram-
ming, expansion and differentiation processes will result
in the need to develop better strategies for reducing
or eliminating genetic and epigenetic variations that
have been observed to change molecular and func-
tional properties of iPSCs and their derivatives. In this
regard, naïve-state cell reversion technology has
emerged as a promising candidate for resolving these
issues, but further advances are needed to improve the
efficiency of reversion and stabilization protocols [19].
Despite rapid progress in the gene-editing field,
limitations related to gene-editing efficiency and speci-
ficity will result in the need to develop more precise
ex vivo vector delivery systems [12,20,21]. Advances
in this area will widen opportunities for reducing the
frequency of off-target mutagenesis and cell
genotoxicity events and for applying the technology
to non-replicating cells (such as iPSC-derived neurons
and cardiac myocytes) to extend the application to a
broader spectrum of genetic diseases.
Immunogenicity potential in the autologous or al-
logeneic setting arises from the relative immaturity of
PSC-derived somatic cells and changes to epigenetic
and protein expression levels in differentiated cells that
can arise from reprogramming, culturing and gene
editing [5,22,23]. Current challenges are centred on
reducing or avoiding the need for immunosuppres-
sion and improving the engraftment or persistence of
PSC-derived therapeutic cells. Continued expansion
in the understanding of the immune response to iPSC
derivatives and to the progeny of gene-corrected iPSCs,
in terms of the type and amount of gene expression
differences between iPSC-derived cells and their in vivo
counterparts that can be tolerated after transplanta-
tion, will bring the need for further advances in
methods for inducing cell maturation ex vivo (i.e., for
the relevant to disease or organ) and for modifying
the immune tolerance of iPSC-derived and gene-
edited cells.
Challenges to advancing the manufacturing
maturity within the PSC therapeutic space
As a path to the early market application of these can-
didate PSC-derived product technology concepts, a
necessary level of manufacturing maturity is re-
quired to enable the industrialization and transfer of
their underlying enabling technologies into a robust,
scalable production system design. By enabling the de-
livery of new product technology capability in a defined
sequence of processing events, predictable manufac-
turing costs and schedules, reproducible levels of
performance between manufacturing runs can be
achieved.
Supported by an increasing contract manufactur-
ing organization capacity and an expanding number
of trade and standards organizations, specialized equip-
ment manufacturers and cell therapy manufacturing
and development services (the industrial base), current
advances in manufacturing technologies are begin-
ning to demonstrate incremental improvements in
manufacturing process maturity and productivity
[24,25]. The emergence of a range of closed-system
devices and automated modular platforms that can be
applied to simplify and automate specific upstream and
downstream parts of the manufacturing process (e.g.
cell enrichment, expansion, harvesting or purification)
Figure 2. Snapshot of TRLs assessing the maturity of critical technology elements for the development of PSC-derived cell and gene-
based product technology candidates. Each box represents the assignedTRL (where technology moves through nine phases: concept exploration
[TRL1–2], concept validation [TRL3–4], prototype development [TRL5], pilot production and demonstration [TRL6–7], production and
market introduction [TRL8] and production and distribution [TRL9]). Green boxes indicate that all required outputs have been achieved
and amber boxes indicate some shortfalls in required outputs. Assignment of TRL is not absolute and is meant as an indicator of the rel-
ative product development program risk and need for further development milestones, which may also be application/indication specific.
This represents a high-level evaluation of TRLs based on an adaptation of the US Department of Defence TRL scheme [16]. (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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has gone some way to resolving fundamental manu-
facturing challenges for the production of somatic cells
(i.e., as a cell therapy or starting material for iPSC
generation), adult stem cells (relative MRL 7–8) and,
to a lesser extent, hESCs (maturity transitioning to
MRL 4; Figure 3) [26]. However, as these first-
generation cell-based therapies begin to reach the
market, the continued pressure to reduce cost of goods
(CoGs) and to improve productivity per unit cost
remains a key challenge and is the primary current
focus of the industry.
For the next wave of potentially personalized, en-
gineered cell-based products that may emerge in the
PSC therapeutic space, the transition from a craft phase
to an industrial phase of biological engineering, with
the convergence of manufacturing system automa-
tion, synthetic material discovery and gene/cell state
manipulation, is set to challenge the readiness and ca-
pability of the existing manufacturing technology and
industrial supply chain base. An understanding of the
manufacturing risks emerging in this space [3] brings
into view a number of new and additional chal-
lenges that need to be addressed to transition relatively
immature underlying enabling technologies (MRL
1–MRL 2) to a level of readiness sufficient to enable
pilot Good Manufacturing Practice (GMP) (pre)pro-
duction to support phase 1 clinical trials (MRL 5).
The snapshot in Figure 3 provides an equivalent high-
level view of the level of manufacturing maturity across
five major PSC-derived product technology concept
areas, based on the intrinsic capability features of the
underlying technologies for integration into a system
or sub-system for production of the overall product
assembly. A consideration of the main manufactur-
ing risks, related to system design, materials
manufacturability, process capability, cost and infra-
structure, allows the following future perspectives for
transitioning manufacturing maturity within the PSC
therapeutic space to be drawn.
Key areas for manufacturing focus
Ipsc reprogramming methods and equipment
Advances in reprogramming methods now provide
multiple candidate vectors for gene delivery, with the
field shifting toward safer and accelerated chemical and
physical non-integrative techniques, under defined
xeno-free culture conditions [17,18]. Increasingly, such
Figure 3. Snapshot of MRLs, assessing manufacturing maturity and the risk for production of the overall PSC-derived cell and gene-
based product candidate assemblies. Each box is used to separately trace the maturation progress in each of the cross-cutting risk areas as
MRLs increase from MRL1 through MRL10 (concept and feasibility analysis [MRL1–4], technology development [MRL5–6], engineer-
ing and manufacturing development [MRL7–8], production and deployment [MRL9] and operations and support [MRL10]).The lowest
MRL is used to assign the overall MRL for the identified core processing areas. Assignment of MRL is not absolute and is meant as an
indicator of the relative manufacturing risk and need for further development milestones, which may also be application specific (e.g., pro-
duction of cells or organoids).This represents a high-level evaluation of MRLs based on an adaptation of the US Department of Defence
MRL scheme [26].
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scientific advances are yielding commercially avail-
able non-integrative reprogramming, kit-based
protocols and services. Generally, however, these
methods remain highly inefficient and labor-intensive
and are often undermined by slow kinetics and poor
ex vivo control of programming factor presentation and
kinetics [18,27].
Continued advances in the mechanistic ‘-omics
level’ understanding of the hierarchical events under-
lying reprogramming processes will extend
opportunities for enhancing kinetics and efficiencies
[28,29]. Clarification of the metabolites (metabolomics)
underlying reprogramming mechanisms, for example,
may enable the development of new reprogramming
parameters for enhancing the generation of fully re-
programmed human iPSCs [29]. Further advances in
the discovery and development of new chemically
defined or artificial reprogramming factors and in cor-
responding 3D biomaterial–based platforms for
controlling spatiotemporal precision delivery of re-
programming factors will be needed to improve the
scalability and reproducibility of the technology.
Enabling the development of simplified iPSC repro-
gramming methods, this will bring opportunities to
make the technology more amenable to automation
and to implementation in GMP settings, while driving
down the CoGs for vector materials.
Beyond improvements in reprogramming efficien-
cy, continued discovery and understanding of the
donor-dependent and patient-specific factors that in-
fluence the lineage differentiation propensity, organoid
self-assembly and functional capacity of iPSCs and their
derivatives [30,31] will result in the need to develop
standardized screening and selection criteria for donors
and patient-specific starting materials (somatic cells).
Further developments in this area are required to
improve the ability to consistently produce iPSCs and
their terminally differentiated derivatives to the re-
quired specifications for allogeneic (e.g., human
leukocyte antigen [HLA]-matched iPSC lines) and
patient-specific applications [23,32].
Continuing growth in the field will result in the
need for extra manufacturing capability and capaci-
ty to meet an increasing demand for the cost-effective
production and supply of quality-assured viral and non-
viral vectors. Up-scaling production and closing the
material quality gap will be critical to reducing qual-
ification and validation efforts of cell therapy
manufacturers.
Ipsc expansion and differentiation methods and
equipment
The development of the first fully GMP-compliant pro-
tocol for manufacturing iPSC lines for potential clinical
use represents significant progress in this area [33],
but underscores the need for further advances in tech-
nology development to reduce CoGs, exclude
heterogeneity in starting materials, improve repro-
gramming efficiencies, reduce variation between
manufacturing runs and improve the resolution of
genomic stability testing performed for quality control
(QC) and release.
As part of the manufacturing chain, further ad-
vances are required in the development of alternative,
scalable cold chain and biopreservation methodolo-
gies that can be shown to have minimal impact on
reprogramming, proliferation and directed differen-
tiation efficiencies, as well as the cellular properties
of the final product. This will reinforce the need for
technological solutions to maintain and orchestrate
complex supply chains and support ‘needle-to-
needle’ traceability.
In terms of scalability, the PSC field is progres-
sively moving from 2D flat surfaces (flasks/plates) to
suspension cell cultures in stirred-tank/microcarrier–
based bioreactors, but the transfer to larger-scale
geometries remains a fundamental challenge. Over-
coming mass transfer and metabolic constraints, which
currently limit the level of cell expansion and differ-
entiation process intensification that can be achieved,
will provide a path to reducing the CoGs associated
with current craft-based media exchange strategies and
to improving industrial scale-up potential [34].
Conventional 2D flask/plate–based protocols are
available for the directed differentiation of iPSCs into
a wide range of cell lineages and 3D tissue–specific
organoid structures. Current iPSC differentiation ef-
ficiencies, however, are still highly variable and can
produce a heterogeneous mixture of partially repro-
grammed ‘defective’ cells and undifferentiated cells.
So too are current organoid derivation protocols, which
rely on uncontrolled, spontaneous morphogenesis pro-
cesses at the microscale and yield inconsistences in
macroscale organoid morphology, cyto-architecture and
cellular composition.This currently limits their stan-
dardization and clinically relevant application [35].
A range of manufacturing techniques, relying on
positive and negative selection procedures (e.g. cell
sorting), using relevant selective markers or reporter
gene expression can be used to enrich for the target
phenotype in the final product [21], However, further
technology advances are required to overcome limi-
tations with current analytical techniques and molecular
characterization methods, which are not reliably sen-
sitive enough to sufficiently define a heterogeneous cell
population that may contain cells in different dynamic
states and with tumourigenic or immunogenic poten-
tial [36]. Continued development of alternative
approaches, such as the use of a suicide gene or other
safety checkpoints, will result in the need for the de-
velopment of more sophisticated, scalable downstream
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automated technologies that can be used to detect and
selectively eliminate unwanted or transformed cells ex
vivo in GMP settings [37–39].
Continued advances in the discovery, design and
engineering of chemically defined, synthetic bioma-
terial substrates and soluble morphogenic analogues
will result in the need for the development of more
dynamic bi-phasic bioreactor systems, which can extend
and exploit better control over the behavior of iPSCs
during ex vivo culture and differentiation. With the
ability to rationally tailor chemical and mechanical
signals in 3D/4D controllable configurations to main-
tain self-renewal, to induce cell lineage-specific
differentiation or to enhance functional maturation,
this will represent a step change toward widening scal-
able and cost-effective ex vivo production options for
iPSCs and tissue-specific organoids for clinical
application.
Gene-editing methods and equipment for ex vivo
modification of iPSCs
With approximately two dozen tool and kit service
companies now offering CRISPR/Cas9-related prod-
ucts, the CRISPR/Cas9 nuclease system is emerging
as the most accessible system for precision genome
engineering, although there are still uncertainties related
to the licensing and commercial use of the technology.
Continued expansion in the mechanistic under-
standing of the CRISPR/Cas9 nuclease system (as well
as the zinc-finger nuclease [ZFN] or transcription
activator-like effector nuclease [TALEN] technolo-
gies) will widen opportunities for integrating the
technology into commercial production systems.
However, with a complex mix of active substances, re-
agents and critical raw materials, further advances in
the ability to measure and characterize the process (i.e.,
critical process parameters and material attributes) and
the product output (i.e., critical quality attributes of
the genetically modified cell phenotype) are needed.
This will drive improvements in the precision and
CoGs and enable the development of manufactur-
ing QC and release strategies in GMP settings.
Product and process characterization and control
technologies
At a fundamental level, further advances in validatable
measurement and characterization technology are
needed to overcome limitations of current analytical
methods and approaches for characterizing the func-
tional identity of therapeutically relevant cell
populations. Such advances would need to be ex-
tended to detecting the level of cellular impurities
(residual undifferentiated or partially differentiated
iPSCs or partially reprogrammed somatic cells, for
example) and to detecting the level and significance
of genetic aberrations at both the level of process de-
velopment (e.g., to verify integrity of starting materials,
intermediates and drug substances) and in the final
drug product.These advances will extend the oppor-
tunity to develop specifications for cellular starting or
input materials that are deterministic of reprogram-
ming, gene editing and expansion or differentiation
outcomes, which will be key for establishing compa-
rability parameters and facilitating the mutual
recognition of clinical-grade iPSC lines as a starting
material for iPSC-derived therapies.This will be a crit-
ical first step to reducing the production costs attributed
to need for multiple levels of QC and assurance
throughout the manufacturing process [40] and for
the demonstration of product comparability.
Further advances in 3D manufacturing process
technology and continued expansion in the discov-
ery of biomarkers and reporter genes for target or
contaminant cells and other potential surrogates of cell
quality (e.g., signalling molecule patterns or exosomes
into culture media) will result in the need for more
sophisticated real-time process analytical technolo-
gy, non-destructive sampling and test systems as well
as quantitated imaging. Such analytical advances will
expand opportunities to apply new mechanistic system
modelling approaches to the development of feedback-
control methods to support data-driven adaptive and
automated manufacturing processes.These may rely,
for example, on the measurement of variability in gene
expression signatures of cell input material, purity ratios
of cell populations, cytokine activity patterns, ‘omic’
biomarker levels or rates of biochemical change and
their influence on cell identity, purity and potency [34].
Advances in measurement and characterization
technologies will reinforce the need for correspond-
ing advances in data analytics and management
technology. Combined with the development of more
strongly integrated patient registries and standard-
ized data collection infrastructures (including relevant
biobanks), this will enhance the scientific and clini-
cal understanding of the safety and effectiveness of
these newly emerging products for multiple
stakeholders.
Accelerating manufacturing readiness–
requirements for manufacturing science
Anticipation of technology innovation trajectories and
their impact on future product development within
the PSC therapeutic space has provided a useful future
perspective on the readiness of current industrial manu-
facturing process technology, equipment and
operational infrastructure to deal with the longer and
more complicated processes that will be involved in
the production of the next generation of advanced cell
therapies.
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This new generation of high-value, disruptive re-
generative medicines will demand a higher level of
production system efficiency, reliability and opera-
tional performance. In the iPSC situation, for example,
implementing the multiple technologies and the highly
complex sequence of processing steps involved in cel-
lular reprogramming, gene editing, expansion and
differentiation into a GMP environment adds a greater
level of complexity and lengthens the time required
to produce high-quality, functionally mature termi-
nally differentiated cells.With the implicitly sensitive
and variable nature of multiple cellular material process
inputs, this makes process consistency and product
comparability much more difficult to achieve.The need
for a specific set of reagents, a different sequence of
steps, perhaps exploiting 3D culture settings, a
decoupling inventory step or a special final formula-
tion for each terminally differentiated cell type adds
significantly to this complexity.
It is this complexity that will drive the need for more
flexible or reconfigurable production systems that are
able to support long-term and parallel processes for
the manufacture of multiple diverse cell types of varying
batch sizes.This will result in the need to develop new,
more agile and adaptive process technologies and
equipment that can deliver new levels of perfor-
mance and flexibility. Corresponding advances in
operational plant design, systems integration and in-
strumentation will be needed to maintain control and
integrity of product and process flows. Simply build-
ing bigger and better manufacturing facilities will not
be enough. Instead of manufacturing in dedicated fa-
cilities (or even designated cleanrooms), advances in
the development of closed-processing systems will allow
manufacturing to happen in spaces where multiple
pieces of equipment can be integrated to manufac-
ture multiple therapies in close physical proximity.
From an engineering standpoint, to take this
advance to a greater level of understanding of the
manufacturing process and the interplay between the
required product specifications and the achievable
process capability will be central to developing a scal-
able production system that can deliver a product with
controllable functional metrics. Advances in measure-
ment and characterization technologies, by improving
understanding of the increasingly complex product,
will be needed to drive an increase in precision and
process control. In this context, significant develop-
ment and innovation within manufacturing science are
the only way that the regenerative medicine sector will
move from ‘the process is your product’ paradigm to
more certainty in process execution [41].
Putting all these perspectives together, the regen-
erative medicine sector is beginning to enter the next
phase of its development. While the industry has
previously focused its attention with respect to
manufacturing on incremental innovation and cost re-
duction, the hope is that the emphasis of future
manufacturing science is targeted at manufacturing
and supply chain challenges, not because they are easy
but because they are hard and will add value to the
industry. Given the leadership, funding, time and com-
mitment, this will be the only way to accelerate
technology and manufacturing readiness for the next
generation of disruptive, high-value cell therapeu-
tics, recognizing that a significant parallel effort will
be needed to transform the organizational and insti-
tutional readiness for adopting and implementing these
emerging and potentially disruptive therapies.
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